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T	cells	 (NFATs),	has	been	suggested	as	an	alternative,	 safer	approach	 to	CN	 inhibi-
tors.	However,	small	chemical	 inhibitors	of	NFATs	have	only	rarely	been	described.	
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1  |  INTRODUC TION




cyte	 reactivity,	 neurofibrillary	 tangles,	 and	 cognitive	 loss	 (Abdul	
et	al.,	2010;	Reese	&	Taglialatela,	2011;	Sompol	&	Norris,	2018).	In	
experimental	models	of	Aβ	pathology,	CN	plays	a	causative	or	ex-




2016;	 Furman	 et	 al.,	 2012;	 Jin	 et	 al.,	 2012;	 Norris	 et	 al.,	 2005;	
Rojanathammanee	 et	 al.,	 2015;	Dos	 Santos	 et	 al.,	 2020;	 Sompol	
et	al.,	2017;	Taglialatela	et	al.,	2009;	Wu	et	al.,	2010,	2012).	In	fact,	
many	AD-	related	biomarkers	are	reversed	or	ameliorated	in	exper-
imental models by treatment with commercial CN- inhibiting im-
munosuppressant	drugs,	such	as	tacrolimus	(Dineley	et	al.,	2007,	
2010;	Kuchibhotla	et	al.,	2008;	Stallings	et	al.,	2018;	Taglialatela	
et	 al.,	 2009).	 Moreover,	 an	 epidemiological	 study	 found	 that	
human	kidney	transplant	patients	treated	with	tacrolimus	exhibit	a	











raised suggest that alternative CN- related targets may provide a 
safer approach for clinical applications beyond allograft transplant 
cases and autoimmune disorders. The nuclear factor of activated T 
cells	(NFAT)	is	one	of	the	best-	characterized	and	most	widely	stud-
ied	CN	 substrates.	NFATs	 reside	 in	 the	 cytosol	when	 intracellular	
Ca2+	 levels	 are	 low,	 but	 translocate	 to	 the	 nucleus	 upon	 binding	
and	dephosphorylation	by	CN.	 In	 the	nucleus,	NFATs	 regulate	 the	










tory	 settings	 to	 prevent	CN/NFAT	 interactions,	without	 inhibiting	
CN activity per se.	The	most	frequently	used	peptide	for	this	purpose,	
VIVIT	(Aramburu	et	al.,	1999),	improves	many	AD-	related	biomarkers	
in	experimental	models	of	Aβ pathology and/or neurodegeneration 
(Furman	et	 al.,	 2012;	Hudry	et	 al.,	 2012;	Rojanathammanee	et	 al.,	
2015;	Sompol	et	al.,	2017),	similar	to	what	is	observed	for	CN	inhib-
itors.	However,	 the	 translational	potential	of	VIVIT	will	 very	 likely	
be limited by many of the same issues that plague other peptide/
protein-	based	 reagents	 (i.e.,	 poor	 stability,	 susceptibility	 to	 oxida-
tion/hydrolysis,	 short	 half-	life,	 poor	 oral	 availability,	 and/or	 poor	
blood-	brain	barrier	penetrance;	Lee	et	al.,	2019).
Although	 small	 chemical	 compounds	 can	 provide	 many	 phar-
macokinetic	 advantages	 over	 peptide/protein-	based	 drugs,	 small	
chemical	 inhibitors	 of	NFAT	activity	 (i.e.,	 independent	of	CN	 inhi-
bition)	have	only	rarely	been	described	(Sieber	&	Baumgrass,	2009).	
Dipyridamoles,	 which	 exhibit	 anti-	blood	 clotting	 and	 anti-	cancer	
properties,	have	been	shown	to	inhibit	NFAT	signaling	in	several	dif-












(Sieber	 et	 al.,	 2007),	 but	 little	 information	 is	 available	 regarding	
the impact of this compound in intact animals. It remains unclear 
whether	any	of	these	NFAT	modulating	agents	lead	to	other	adverse	
effects commonly associated with CN inhibitor drugs.




and	 can	 be	 safely	 administered	 to	 experimental	 subjects	 across	 a	
wide	dosing	range	(e.g.,	the	LD50	is	>90mg/kg	in	mice).	A	Phase	1a	




we	 show	 that	 Q134R	 partially	 inhibits	 NFAT	 activity	 in	 primary	





to	 reduced	NFAT4	 expression	 in	 astrocytes,	 reduced	 glial	 reactiv-
ity	markers,	and	improved	synaptic	function	and	plasticity,	without	
affecting	Aβ load. The results are consistent with previous studies 
that	have	advanced	CN/NFAT	inhibition	as	an	alternative	AD	treat-
ment,	and/or	as	a	complimentary	strategy	 to	 the	reduction	of	key	
AD	 pathologic	 hallmarks	 (i.e.,	 using	 amyloid-	lowering	 biologics).	
Moreover,	the	lack	of	effect	on	CN	activity,	together	with	few	signs	
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of	 toxicity,	 suggests	 that	Q134R	 could	 produce	 similar	 neurologic	
benefits	compared	with	CNIs,	with	fewer	adverse	effects.
2  |  RESULTS
2.1  |  Q134R inhibits NFAT activity in astrocytes 
but has little to no effect on CN activity
Q134R is a cytoprotective and blood– brain barrier permeant hy-
droxyquinoline	 derivative	 (Figure	 1a)	 developed	 by	 Avidin	 Ltd	
(Hackler	et	al.,	2019;	Kanizsai	et	al.,	2018)	and	found	safe	for	human	
consumption	 following	a	Phase	1A	clinical	 trial	 (EudraCT	Number:	
2016-	000368-	40).	 Initial	 studies	 tested	 Q134R	 in	 the	 Cerep	
Diversity panel composed of binding and functional assays for ion 
channels,	 neurotransmitter	 receptors,	 enzymes	 (including	 25	 Zn-	
ion	containing	enzymes),	peptidases,	and	kinases	along	with	other	
targets related to neuroprotection/neurodegeneration (data not 




ester	(IPE,	0.5	μM),	to	elevate	intracellular	Ca2+ levels and stimulate 
CN	activity,	was	 inhibited	 in	a	dose-	dependent	manner	by	Q134R	
(IC50	of	566	nM;	Figure	S1a).
CN/NFAT	 affects	 neural	 function	 in	 disease	 models	 through	
multiple	 cell	 types	 including	 neurons	 (Hopp	 et	 al.,	 2018;	 Hudry	




(Canellada	 et	 al.,	 2008;	 Fernandez	 et	 al.,	 2007;	 Furman	 et	 al.,	
2012;	Norris	et	al.,	2005;	Perez-	Ortiz	et	al.,	2008;	Sama	et	al.,	2008;	
Serrano-	Perez	 et	 al.,	 2011;	 Sompol	 et	 al.,	 2017).	 For	 our	 initial	




(e)	Mean	±	SEM	NFAT-	luciferase	expression	(%)	in	primary	astrocytes	treated	with	10	ng/ml	IL-	1β in the presence of increasing Q134R 
concentrations.	Q134R	inhibited	astrocytic	NFAT	signaling	in	a	concentration-	dependent	manner.	(f)	Representative	western	blot	for	total	
Cx43,	dpCx43,	and	Na/K	ATPAse	loading	control	in	primary	astrocytes	treated	with	Veh,	or	10	ng/ml	IL-	1β in the presence/absence of 5 μM	
CsA	or	10	μM	Q134R.	Full	blots	are	shown	in	Figure	S2.	(g)	Mean	±	SEM	dpCx43	levels	(%	of	Veh)	under	the	conditions	shown	in	panel	f.	CsA	
inhibited	dephosphorylation	of	Cx43,	but	Q134R	did	not.	(h)	Mean	±	SEM	PO4 released from a synthetic phosphopeptide in response to in 
vitro	CN	activity.	Dephosphorylation	is	inhibited	by	CN-	AIP	(100	μM),	but	not	by	Q134R.	For	panels	b-	e,	n	=	six	35	mm	dishes	per	condition.	
For	panel	h,	n = 4 pooled samples per condition




Perez	 et	 al.,	 2011;	 Neria	 et	 al.,	 2013;	 Furman	 et	 al.,	 2016;	 Pleiss	
et al.	 2016;	 Sompol	 et	 al.,	 2017)	 and	 also	 because	 the	 conditions	




Primary astrocytes were treated for 3 hr with ionomycin/phorbol 




was	strongly	inhibited	by	CsA	(p < 0.0001). Q134R also significantly 
inhibited	NFAT	activity	 (p	<	0.0001	under	 IPE	and	IL-	1β treatment 
and p	<	0.001	under	oAβ	treatment),	albeit	to	a	 lesser	extent	than	
CsA.	 Q134R-	mediated	 inhibition	 of	 astrocytic	 NFAT	 activity	 was	
dose dependent (IC50	 ~400	 nM)	 and	 partial	 (35–	40%	maximal	 in-
hibition)	(Figure	1e).	Using	a	saturating	concentration	of	Q134R,	we	
observed	similar	 levels	of	 inhibition	of	NFAT-	dependent	 luciferase	
activity in primary rat cortical neurons (Figure S1b).
Most	compounds	found	to	inhibit	NFAT	signaling	act	on,	or	up-
stream	of,	CN.	To	assess	whether	Q134R	 is	 a	CN	 inhibitor	we	 in-
vestigated	 the	 CN-	dependent	 dephosphorylation	 of	 a	 non-	NFAT	
substrate in vivo and in vitro (Figure 1f- h). For in vivo measures of 
CN	activity	 (Figure	2f,g),	we	 assessed	 the	CN-	dependent	dephos-
phorylation	of	connexin	43	 (Cx43),	which	occurs	 in	primary	astro-
cytes	in	response	to	injurious	stimuli	(Li	&	Nagy,	2000;	Tence	et	al.,	
2012)	 (Figure	1f,	 also	Figure	S2).	Astrocytes	were	 stimulated	with	
IL-	1β	in	the	presence	or	absence	of	the	CN	inhibitor	CsA	or	Q134R.	
Cx43	levels	were	assessed	using	two	different	antibodies:	one	that	
labels	 total	 Cx43	 (tCx43)	 and	 one	 that	 labels	 Cx43	 only	 when	 it	
is	 dephosphorylated	 at	 Ser368	 (dpCx43)	 (Li	&	Nagy,	 2000;	 Tence	
et	al.,	2012).	 IL-	1β	had	little	effect	on	total	Cx43	levels	but	caused	
a	25–	30%	increase	 in	dpCx43	 levels	 (p	<	0.01),	an	effect	that	was	




at	 the	 same	 concentration	 for	 maximally	 inhibiting	 NFAT	 activity	
(Figure	1e),	Q134R	had	no	effect	on	dpCx43	levels.
To	assess	CN	activity	in	vitro,	the	amount	of	free	phosphate	re-
leased	 from	 a	 synthetic	 phosphopeptide	 substrate	was	 quantified	
in	 the	 presence	 of	 human	CN	Aα/CN B heterodimer activated by 
Ca2+/calmodulin (Figure 1h). The addition of the CN autoinhibitory 







2.2  |  Acute treatment with Q134R improves Y 
maze performance in APP/PS1 mice and wild- type 
mice treated with oligomeric Aβ peptides
Acute	treatments	with	commercial	CNIs,	like	tacrolimus,	have	been	




has	 similar	 cognitive	 enhancing	 effects,	 12-	month-	old	 male	 APP/
PS1	mice	and	3-	 to	4-	month-	old	male	WT	mice	 injected	with	oAβ 
were	administered	Q134R	or	vehicle	across	4–	7	days	and	tested	on	
a	Y	maze.




treatment group) and the results revealed a significant interaction 
between drug treatment and genotype [F(1,34)	=	3.96,	p = 0.05]. 




WT	mice	received	a	single	ICV	injection	of	oAβ42 peptides (50 pmol 
total)	 under	 anesthesia.	 Mice	 were	 then	 recovered	 and	 treated	
twice daily via oral gavage with Q134R (4 mg/kg) or vehicle for four 
additional days before testing on a spontaneous alternation version 
of	the	Y	maze	(Figure	2c,d;	n	=	7–	8	mice	per	condition).	As	shown	in	
Figure	2d,	oAβ injections led to impaired alternation performance 
in the absence of Q134R treatment (p	<	0.001).	However,	no	cog-
nitive	 deficit	 was	 observed	 in	 oAβ42 - injected mice treated with 
Q134R.	 Together,	 these	 observations	 suggest	 that	 acute	 Q134R	
treatment	improves	cognitive	function	in	rodent	models	of	AD-	like	
pathology.
2.3  |  Chronic delivery of Q134R does not alter 
immune cell profiles, but promotes long- term survival




terized,	 in	part,	by	a	drop	 in	 lymphocyte	counts	and	other	white	
blood	cell	changes	 (Gallo	et	al.,	2006;	Khalil	et	al.,	2018;	Koprak	
et	 al.,	 1996).	 Chronic	 lymphopenia	 could	 offset	 possible	 neuro-
logic benefits achieved by long- term CN inhibition. To determine 
if	Q134R	was	associated	with	 lymphopenia,	we	measured	blood	
cell counts in male and female adult mice (~6 months of age) that 
were oral- gavaged twice daily for 12 weeks with vehicle or Q134R 
at	a	dose	associated	with	 improved	cognitive	 function	 (4	mg/kg,	
see Figure 2). Blood samples were collected at baseline (imme-
diately prior to the first dosing session) and then again at 4 and 
    |  5 of 20SOMPOL et aL.




nificant effects on any of the cell types assessed. RBCs showed a 
small decrease across treatment (baseline vs. 12 weeks) for both 




were	 very	 similar	 across	 males	 and	 females.	 Thus,	 unlike	 CNIs,	
chronic treatment with Q134R does not appear to be associated 
with	a	reduction	in	peripheral	immune	cells,	though	there	may	be	
some impact on RBC levels.
To determine if chronic Q134R treatment negatively af-
fects	 mortality,	 we	 treated	 middle-	age	 WT	 female	 mice	 over	
a	 nearly	 2-	year-	long	 period.	 Starting	 at	 52	weeks	 of	 age,	mice	
were	 treated	 daily	 (via	 oral	 gavage,	 4	 mg/kg)	 with	 vehicle	 or	
Q134R (n = 16 mice/group) and followed until death. Kaplan– 
Meier	 curves	 are	 shown	 in	 Figure	 3b	 and	were	 used	 to	 derive	
median	survival,	which	was	greater	for	Q134R-	treated	mice	(124	
vs.	 110	 weeks).	 In	 fact,	 Q134R	 treatment	 promoted	 survival	
across	the	duration	of	treatment	(Log-	rank	test,	p	=	0.06,	Hazard	
ratio	=	1.84;	Gehan–	Breslow–	Wilcoxon	test,	p	=	0.041,	Hazard	
ratio	 =	 2.09),	 though	 lifespan	 was	 not	 appreciably	 extended.	
Together,	the	results	suggest	that	long-	term,	chronic	treatment	
with Q134R is safe.
2.4  |  Chronic treatment with Q134R tends to limit 
glial reactivity in APP/PS1 mice without affecting 
Aβ pathology
We	 next	 investigated	 whether	 long-	term	 treatment	 with	 Q134R	
was associated with beneficial effects on several hallmark brain bio-
markers	of	AD	including	elevated	Aβ	plaque	load,	and	increased	glial	










Although	 female	 APP/PS1	 mice	 exhibited	 greater	 Aβ	 plaque	
loads	 relative	 to	male	mice	 (Table	1,	p	 =	0.01),	 as	 previously	 re-
ported	(Jiao	et	al.,	2016),	no	significant	effect	of	Q134R	was	ob-
served	 for	either	 sex.	Q134R	also	did	not	 affect	Aβ	 plaque	 load	
when	males	and	females	were	combined	 (Figure	4b,	e).	For	 Iba1,	
we found a significant interaction between Q134R treatment and 
transgene	 [F(1,30)	=	5.45,	p	=	0.03)	 (Figure	4c,	 f).	APP/PS1	mice	
exhibited	significantly	greater	 Iba1	 levels	as	expected	 (p = 0.02). 
Within	 the	APP/PS1	group,	Q134R	 tended	 to	 reduce	 Iba1	 levels	
overall (p	=	0.1),	and	no	sex	differences	in	the	extent	of	reduction	






treated	with	vehicle	or	oAβ	in	the	presence	or	absence	of	Q134R.	Q134R	improved	performance	in	oAβ- treated mice. n	=	7–	8	mice	per	
group
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were	observed	(Table	1).	In	contrast,	Q134R	was	associated	with	
a nonsignificant increase in Iba- 1 (p	=	0.18)	in	WT	mice,	mostly	at-
tributable	to	an	elevation	in	females	(Table	1).	For	GFAP,	we	found	
a significant transgene effect F(1,	48)	=	23.67,	indicative	of	greater	
GFAP	levels	in	APP/PS1	mice	(p	<	0.001),	as	expected	(Figure	4d,	
g).	Q134R	had	no	significant	effects	on	GFAP	in	either	transgene	





female	 APP/PS1	 mice	 showed	 a	 slight	 increase	 in	 GFAP	 levels	
with Q134R treatment (Table 1). The results suggest that Q134R 
tends	to	 limit	glial	activation	 in	APP/PS1	mice,	without	affecting	
Aβ levels.
2.5  |  Chronic treatment with Q134R reduces 
NFAT4 expression in astrocytes, but has little effect 
on NFAT4 co- localization with astrocyte nuclei
Several	 NFAT	 isoforms	 have	 been	 implicated	 in	 AD	 pathophysi-
ology,	 two	of	which	 (NFAT3	and	NFAT4)	were	 investigated	here.	
The	 NFAT3	 isoform	 is	 strongly	 associated	 with	 neurons	 where	
it	 is	 thought	 to	mediate	 the	 degeneration	 of	 dendrites/neurons,	
as	well	as	altered	expression	of	synapse-	related	proteins	(Shioda	
et al.	 2006;	Wu	et	al.,	2010;	Hopp	et	 al.,	2018).	The	NFAT4	 iso-






their	 respective	cell	 types.	However,	neither	 transgene	nor	drug	
treatment	had	a	discernable	effect	on	NFAT3,	which	was	almost	
totally confined to the dendritic regions of neurons and showed 
very	little	co-	localization	with	neuronal	nuclei	(Figure	S3).	In	con-
trast,	NFAT4	labeling	(Figure	5a,	5d)	was	significantly	affected	by	
both	transgene	[F(1,51)	=	27.43,	p < 0.0001] and drug treatment 
[F(1,51)	=	5.71,	p	=	0.02].	Astrocytes	in	APP/PS1	mice	showed	sig-
nificantly	greater	NFAT4	labeling	relative	to	WT	mice	(p	<	0.0001,	
Figure 5d) and Q134R caused a significant reduction in total 




inhibiting	 peptide,	 VIVIT,	 directly	 to	 astrocytes	 reduced	 NFAT	
nuclear	localization	in	the	5xFAD	model	(Sompol	et	al.,	2017).	As	
F I G U R E  3 Chronic	treatment	with	
Q134R has little effect on white blood 
cell counts and enhances survival in adult 
mice.	(a)	Table	showing	mean	±	SEM	
peripheral blood cell counts in 6- month- 
old	WT	mice	measured	before	and	at	4	
and	12	weeks	during	treatment	(2×	daily,	





effects of drug treatment or timepoint 
were	found,	except	for	RBCs,	which	
showed a slight decrease in Q134R mice 
at 12 weeks relative to baseline. n	=	9–	
10 mice per group; *p	<	0.05,	within	group	
comparison of baseline vs. 12- week time 
point.	(b)	Kaplan–	Meier	curves	for	WT	
mice	gavaged	with	Veh	or	Q134R	(Q1,	
4 mg/kg). Drug treatment was initiated at 
52 weeks of age and mice were followed 
until time of death. Q134R enhanced 
survival across the lifespan. n = 16 mice 
per group
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shown	 in	Figure	5b,	 5c,	 and	5e,	NFAT4	 localization	 to	 astrocyte	
nuclei	was	elevated	in	APP/PS1	mice	(Figure	5e	p	=	0.02),	but	was	




of action remains unclear.
2.6  |  Chronic treatment with Q134R improves 
synaptic function in APP/PS1 mice
Electrophysiologic	indices	of	synaptic	transmission	are	exquisitely	
sensitive	to	brain	injury	and	pathology	and	are	frequently	used	to	
assess drug effects on brain function. Deficits in the most com-
monly	 investigated	 synaptic	 measures,	 basal	 synaptic	 strength	
and/or	 long-	term	 potentiation	 (LTP),	 are	 usually	 ameliorated	 by	
inhibition	 of	 CN	 or	 NFATs,	 via	 genetic	 or	 pharmacologic	 means	
(Chen	et	al.,	2002;	Dineley	et	al.,	2010;	Furman	et	al.,	2012,	2016;	
Sompol	 et	 al.,	 2017).	 To	 determine	 if	 Q134R	 is	 associated	 with	
similar	 synaptoprotective	 properties,	 we	 collected	 electrophysi-
ologic	recordings	from	CA1	stratum radiatum in acutely prepared 
coronal	 brain	 slices	 from	 9-	month-	old	 male	 and	 female	 APP/
PS1	mice	 and	WT	 littermates	 treated	 for	 3	months	with	Q134R	
(4	mg/kg,	2×/day	P.O)	or	vehicle	as	described	in	Figures	4-	5.	Field	
potentials	in	CA1	were	elicited	in	response	to	prodromal	electrical	
stimulation of Schaffer collateral/commissural fibers (Figure 6a- 
c). Several synaptic parameters including basal synaptic strength 
(synaptic	 strength	 curves	 shown	 in	 Figure	 6d	 and	 6f;	 maximum	
EPSP/FV	 ratio	 shown	 in	 Figure	 6h),	 LTP	 (time	 plots	 shown	 in	
Figure	6e	and	6g,	mean	LTP	levels	shown	in	Figure	6k),	population	
spike	(PS)	threshold	(Figure	6i),	and	paired	pulse	facilitation	(PPF)	
(Figure 6j) were measured and compared across treatment groups 
(n	=	8–	14	mice,	per	treatment	group).
As	 expected,	 both	 synaptic	 strength	 (p	 <	 0.05)	 and	 LTP	
(p	 <	 0.05)	 were	 reduced	 in	 vehicle-	treated	 APP/PS1	 mice	 rela-
tive	to	their	WT	counterparts.	Q134R	ameliorated	each	of	these	
effects:	 that	 is,	 treatment	 of	APP/PS1	mice	with	Q134R	 shifted	
the	synaptic	strength	curve	to	 the	 left	 (Figure	6f),	 increased	the	
EPSP-	to-	FV	ratio	(Figure	6h),	and	enhanced	LTP	levels	(Figure	6g	
and	 6k).	 In	 contrast,	 Q134R	 caused	 a	 small,	 albeit	 insignificant,	
reduction	in	synaptic	strength	and	LTP	in	WT	mice.	No	transgene	
or	drug	effects	for	PS	threshold	(a	measure	of	neuronal	excitabil-
ity) and PPF (a measure of short- term plasticity) were observed 
(Figure	 6i	 and	 6j,	 respectively).	 Electrophysiological	 results	 are	




to be greater in males and showed greater recovery with Q134R 
treatment.	The	results	demonstrate	that,	like	CN/NFAT	inhibitors,	
Q134R	 protects	 synaptic	 function	 in	 mouse	 models	 of	 AD-	like	
pathology.
3  |  DISCUSSION
This study conducted both in primary cell cultures and in intact mice 
demonstrated	 that	 the	 novel	 hydroxyquinoline	 compound	Q134R	
exhibits	NFAT	 inhibitory	properties	 in	 the	absence	of	CN	modula-
tion.	In	an	intact	mouse	model	of	AD-	like	amyloid	pathology,	Q134R	
reduced	the	expression	of	the	NFAT4	isoform,	which	is	typically	up-
regulated in reactive astrocytes. Similar to peptide- based inhibitors 
of	NFAT	(i.e.,	VIVIT),	Q134R	improved	cognitive	and	synaptic	func-
tion,	 and	 generally	 promoted	 survival	 beyond	 mid-	age.	 Recently,	





3.1  |  Q134R and NFAT signaling
Q134R	 is	 a	 novel	 8-	hydroxyquinoline	 derivative	 recently	 shown	
to	exhibit	 cytoprotective	effects	along	with	HIF-	1A	stabilization	
properties	 (Hackler	et	al.,	2019).	Further	preliminary	analyses	of	
Q134R	 activity	 against	 >150	 cellular	 targets	 revealed	 CN/NFAT	
signaling	as	a	possible	“hit.”	This	study	is	the	first	to	characterize	
TA B L E  1 Immunolabeling	measures:	Drug	×	Sex	effects	within	
genotype groups






M - - - - 0.38	±	0.09 0.49	±	0.14
F - - - - 0.92	±	0.2b  0.97	±	0.22
GFAP
M 1.06	±	0.16 0.92	±	0.22 2.23	±	0.28 1.60	±	0.25
F 1.22	±	0.29 1.73	±	0.39 3.09	±	0.40 3.14	±	0.28c 
Iba1
M 1.43	±	0.60 0.91	±	0.35 2.22	±	1.42 1.32	±	0.42
F 1.26	±	0.39 2.91	±	1.16 2.74	±	0.55 1.63	±	0.58
NFAT4/GFAP
M 0.53	±	0.06 0.40	±	0.04 0.90	±	0.14 0.8	±	0.14
F 0.58	±	0.10 0.78	±	0.16a  1.27	±	0.17 0.94	±	0.15
NFAT4/DAPI
M 0.67	±	0.13 0.74	±	0.24 1.24	±	0.26 1.01	±	0.20














activation in astrocytes with injury and amyloid pathology (Furman 
et	al.,	2016;	Serrano-	Perez	et	al.,	2011;	Sompol	et	al.,	2017)	and	
show	 reliable	 activation	patterns	 in	primary	 cultures	 (Fernandez	
et	al.,	2007)	Sama	et	al.,	2008;	Abdul	et	al.,	2009;	Furman	et	al.,	
2010).	 In	 primary	 astrocytes,	 Q134R	 inhibited	 NFAT	 transcrip-
tional	regulation	in	response	to	exogenous	Ca2+	mobilizing	agents,	
and	 to	 pathogenic	 extracellular	 factors.	 Q134R-	mediated	 inhi-
bition	 of	NFAT	 activity	was	 dose-	dependent,	 but	 only	 partial	 in	
extent.	As	 a	 potential	 therapeutic	 strategy	 for	managing	 neuro-
degenerative	 disorders,	 it	 is	 notable	 that	 Q134R	 had	 no	 appar-
ent direct effects on CN activity in vitro or in vivo,	suggesting	that	
Q134R acts downstream of CN activation. These observations 
suggest that Q134R could be used to target key CN- mediated del-
eterious processes without triggering many of the adverse effects 
commonly	 ascribed	 to	 commercial	CN	 inhibitors	 (Farouk	&	Rein,	
2020;	Khalil	et	al.,	2018)	(see	additional	discussion	below).
3.2  |  Effects of Q134R on intact mice
During	 the	 preclinical	 development	 of	 Q134R,	 2-	week	 repeated	
dose	 toxicity	 studies	 (with	 2-	week	 follow-	up	 periods)	 were	 con-
ducted	in	the	Wistar	rat	and	the	Beagle	(data	not	shown).	Overall,	
Q134R was devoid of major effects on the cardiovascular and cen-
tral	nervous	systems.	The	determined	“No	Observed	Adverse	Effect	





ventricular	 injection	 of	 oAβ peptides. The cognitive enhancing ef-
fects of Q134R were very similar to that reported for amyloid mouse 
models	 treated	with	 commercial	CNIs	 (Dineley	 et	 al.,	 2007,	 2010;	
Taglialatela	et	al.,	2009)	suggesting	a	common	mechanism	of	action	
between Q134R and CNIs.
A	major	downside	to	CNIs	for	the	treatment	of	progressive	neu-
rodegenerative diseases is the systemic immunosuppression and 
toxicity	 that	 develops	 with	 chronic	 use.	 However,	 in	 contrast	 to	
CNIs,	long-	term	delivery	of	Q134R	in	mice	elicited	few	obvious	ad-
verse	effects.	Indeed,	Q134R	was	well	tolerated	when	given	orally	
F I G U R E  4 Chronic	treatment	with	Q134R	reduces	tends	to	limit	glial	activation,	but	does	not	alter	Aβ	plaque	load.	(a)	Illustration	of	
experimental	treatment	conditions.	Six-	month-	old	APP/PS1	mice	were	oral	gavaged	2×/day	with	vehicle	(Veh)	or	Q134R	(4	mg/kg)	for	
3	months.	At	the	endpoint,	one	brain	hemisphere	was	formalin-	fixed	for	immunolabeling,	while	the	other	hemisphere	from	some	mice	was	
used for the preparation of in situ brain slices for hippocampal electrophysiology (Figure 6). (b) Confocal micrographs showing labeling for 
Aβ1- 42	in	neocortex	of	APP/PS1	mice	treated	with	vehicle	(Veh)	or	Q134R	(Q1)	(calibration	bars	=	100	μm). (c and d) Confocal micrographs 
showing	co-	labeling	for	Iba1	(c,	red)	or	GFAP	(d,	green)	in	the	hippocampus	of	WT	and	APP/PS1	mice	treated	with	Veh	or	Q1	(calibration	
bars = 50 and 25 μm).	(e-	f),	Mean	±	SEM	total	labeling	(%	area)	for	Aβ1- 42	(e),	Iba1	(f),	and	GFAP	(g)	in	WT	and	APP/PS1	mice	treated	with	Veh	
(red)	or	Q1	(blue).	Iba1	and	GFAP	were	both	elevated	in	APP/PS1	mice,	as	expected.	Q134R	tended	to	reduce	Iba1	levels	on	APP/PS1	mice,	
but	did	not	significantly	alter	Aβ1- 42	plaque	load	or	GFAP	levels.	n = 13– 15 mice per genotype/drug group
    |  9 of 20SOMPOL et aL.





day with vehicle (Veh) or Q134R (4 mg/
kg) for 3 months as described in Figure 




treated with vehicle (Veh) or Q134R (Q1) 

















astrocyte nuclei. n = 13– 15 mice per 
genotype/drug group
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over many weeks and did not lead to weight loss or progressive 







condition that is generally not associated with tacrolimus or other 
CN	inhibitors.	If	this	reduction	is	confirmed	in	future	studies,	addi-
tional	investigation	will	be	required	to	identify	clinical	symptoms	of	
anemia and determine if the cause is related to impaired production 
and/or	 increased	breakdown	of	red	blood	cells.	Still,	WT	mice	ga-
vaged	daily	with	Q134R	survived	for	many	months,	and	while	ab-
solute lifespan did not differ between placebo and Q134R- treated 
mice,	 survival	 probability	 for	 the	 Q134R	 group	 was	 elevated	 at	
nearly	every	time	point	evaluated	(for	up	to	88	weeks	of	treatment).	
These	 results	 suggest	 that	Q134R	 is	 not	 only	well-	tolerated,	 but	
it	may	have	benefits	beyond	CNS	 function,	highlighting	 the	need	
to	 assess	 the	 cellular	 effects	 of	Q134R	 on	NFATs	 in	 other	 organ	
systems.
Oral administration of Q134R over 3 months reduced signs of glial 
reactivity,	especially	in	microglia.	Significant	reductions	in	Iba-	1	have	
been	 similarly	 reported	 in	 APP/PS1	 mice	 treated	 with	 the	 NFAT-	
inhibitory	 peptide	 VIVIT	 (Furman	 et	 al.,	 2012l	 Rojanathammanee	
et	 al.,	 2015;	Manocha	 et	 al.,	 2017).	 However,	 in	 spite	 of	 reducing	
astroglial	 NFAT4	 expression,	 Q134R	 had	 only	 marginal	 effects	 on	
GFAP	 expression	 (particularly	 in	 females),	 suggesting	 that	 Q134R	
has	 stronger	 effects	 on	 microglia,	 and/or	 modulates	 very	 specific	





mediated delivery of VIVIT produced several beneficial effects on 
neural	function,	without	appreciably	modifying	GFAP	levels	(Furman	
et	al.,	2016).
Chronic Q134R treatment also improved hippocampal synaptic 
function	 and	plasticity	 in	APP/PS1	mice.	 In	 humans,	 synapse	dys-
function/loss	is	a	very	likely	proximal	cause	of	cognitive	decline	in	
the	early	stages	of	AD	and	AD-	related	disorders	(Scheff	et	al.,	2015).	
Consequently,	many,	 if	 not	most,	 promising	 compounds	 for	 treat-
ing	the	clinical	symptoms	of	AD	are	prescreened	in	relevant	animal	
models using electrophysiologic measures of hippocampal synaptic 
transmission.	 Here,	 we	 found	 that	 chronic	 Q134R	 treatment	 im-
proved	both	CA1	synaptic	strength	and	LTP	in	APP/PS1	mice,	sug-
gesting that the cognitive- boosting effects of this compound may 
follow directly from its beneficial actions on synapses. Similar to 
effects	 on	 glial	 markers,	 the	 synaptoprotective	 actions	 of	Q134R	
mirror	 the	 actions	 of	 commercial	 CNIs	 and	 peptide-	based	 NFAT	








(insignificant)	 drug-	related	 deficit	 in	 synaptic	 strength,	 indicating	
that there could be some potential for interfering with functional 
synaptic	connections	in	healthy	animals.	And	though	these	studies	
were	 not	 specifically	 powered	 to	 detect	 sex	 differences,	 Q134R	
tended to affect synaptic parameters differently in males and fe-
males	 (e.g.,	 synaptic	 strength	 and	 LTP,	 Table	 2).	 The	 mechanistic	
basis	for	this	possible	sexual	dimorphism	is	not	clear,	but	should	be	
investigated	more	extensively	in	future	studies.
Finally,	 it	 is	 notable	 that	 despite	 its	 other	 putative	 beneficial	
effects,	Q134R	did	not	significantly	alter	Aβ	plaque	load	in	double	
transgenic	 APP/PS1	mice.	 This	 may	 be	 a	 little	 surprising	 because	
BACE1	 (the	 rate-	limiting	 enzyme	 for	 Aβ production) is transcrip-
tionally	induced	in	astrocytes	by	NFAT4	(Jin	et	al.,	2012).	Moreover,	
systemic delivery of VIVIT peptides and viral- mediated delivery of 
VIVIT	 to	 astrocytes	 were	 shown	 to	 reduce	 Aβ pathology in both 
the	double	transgenic	APP/PS1	mouse	model	(Furman	et	al.,	2012;	
Rojanathammanee	 et	 al.,	 2015)	 and	 the	 more	 aggressive	 5xFAD	
strain	 (Sompol	 et	 al.,	 2017).	 Why	 Q134R	 lacks	 amyloid-	lowering	
properties remains unclear but could relate to the overall weaker 




TA B L E  2 Electrophysiology	measures:	Drug	×	Sex	effects	within	
genotype groups






M 4.10	±	0.93 3.08	±	0.66 2.38	±	0.49 2.60	±	0.57
F 2.25	±	0.58a  2.1	±	0.35 1.61	±	0.27 3.07	±	0.46b 
PPF
M 161	±	11 159	±	12 161	±	12 148	±	10
F 155	±	12 169	±	6 150	±	5 174	±	10
PS Threshold
M 0.45	±	0.10 0.37	±	0.09 0.31	±	0.07 0.27	±	0.06
F 0.23	±	0.03a  0.41	±	0.05 0.27	±	0.04 0.37	±	0.05
LTP
M 154	±	8 152	±	10 112	±	12 167	±	26c
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discussion).	Regardless,	our	findings	are	consistent	with	other	stud-
ies	showing	that	the	reduction	of	Aβ,	at	least	in	preclinical	models,	
is	 not	 a	 prerequisite	 for	 improving	 neural	 function	 and	 cognition	
(Joyashiki	 et	 al.,	 2011;	Middeldorp	 et	 al.,	 2016;	 Tong	 et	 al.,	 2012;	
Voorhees	et	al.,	2018).
3.3  |  Cellular mechanism of Q134R
A	key	unresolved	issue	of	the	present	work	centers	on	the	precise	
mechanism	for	NFAT	inhibition	by	Q134R.	Unlike	the	NFAT	inhibi-
tory	peptide	VIVIT,	Q134R	did	not	 appear	 to	 alter	 the	 subcellular	
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localization	 of	 NFATs	 in	 either	 astrocytes	 (Figure	 5e)	 or	 neurons	
(Figure	 S3b),	 though	Q134R	did	 reduce	 astrocytic	NFAT4	 labeling	
intensity. It is possible that the relatively mild pathology associated 
with	9-	month-	old	APP/PS1	mice,	combined	with	the	milder	NFAT-	
inhibitory	 properties	 of	 Q134R,	 is	 not	 ideal	 for	 obtaining	 easy-	
to-	measure	 differences	 in	 NFAT	 nuclear	 shuttling	 intact	 animals.	
Alternatively,	Q134R	may	inhibit	NFATs	through	a	novel	mechanism.	
Possibilities	include:	disruption	of	NFAT	interactions	with	DNA	bind-




investigations are underway to test each of these possibilities.
Experiments	are	also	underway	to	determine	if	Q134R	similarly	
affects	 different	 NFAT	 isoforms	 expressed	 across	multiple	 neural	
cell types. Initial studies found that saturating levels of Q134R re-
sult	in	similar	levels	of	NFAT	inhibition	in	neurons	(Figure	S1),	where	
hyperactivation	of	 the	NFAT	pathway	has	been	 implicated	 in	AD-	
related	 neurite	 degeneration	 and	 synapse	 dysregulation	 (Hopp	
et	 al.,	 2018;	Hudry	et	 al.,	 2012;	Wu	et	 al.,	 2010,	2012).	Thus,	 the	
protective actions of Q134R in intact animals are probably not 
limited	to	astrocytes.	The	CN/NFAT	pathway	 in	microglia	has	also	
been shown to mediate/modulate pathophysiologic effects relevant 




ilar	 reduction	 in	 Iba-	1	was	observed	 in	APP/PS1	mice	when	VIVIT	
expression	was	limited	specifically	to	astrocytes	using	AAV	vectors	
(Furman	et	al.,	2012),	highlighting	the	extensive	cross-	talk	between	
different cell types in the brain (and the difficulty of pinpointing cell- 
type-	specific	 actions	 of	 pharmacologic	 compounds).	 Finally,	NFAT	
signaling	 in	 other	 cell	 types	 including	 oligodendrocytes	 (Weider	
et	al.,	2018)	and	pericytes	(Blanchard	et	al.,	2020)	has	been	recently	
proposed to modulate myelination and cerebrovascular pathologies 
found in progressive neurodegenerative diseases such as multiple 
sclerosis	and	AD.	Together,	these	observations	provide	an	extensive	
array of possible mechanisms through which Q134R may affect neu-
ral function.
3.4  |  Q134R and non- NFAT targets
An	earlier	study	found	that	Q134R-	stabilized	HIF1A,	a	transcription	
factor	 induced	during	 hypoxic	 conditions.	Cerebral	 hypoperfusion	
and	AD	are	bidirectionally	linked	suggesting	that	HIF-	1A	may	have	
a	central	role	in	AD	pathophysiology	(Ashok	et	al.,	2017;	Ogunshola	
&	 Antoniou,	 2009).	 HIF1A-	dependent	 transcriptional	 regulation	
is	well	known	to	promote	hypoxic	adaptation,	perhaps	through	an	
astrocyte-	based	mechanism	(Hirayama	et	al.,	2015),	which	could	pro-
vide	 compensatory	 neuroprotection	during	 cerebral	 ischemia,	 and	
by	corollary,	 in	AD	 (Singh	et	al.,	2012).	Q134R-	mediated	 improve-











pairments	 in	APP/PS1	mice,	which	 is	 nearly	 the	 opposite	 of	what	
we	observed	 in	 this	 study.	To	 complicate	matters,	 it	 seems	highly	
plausible	that	Q134R’s	effects	on	neural	function	reflect	a	mixture	




resulting	in	little	to	no	modulation	of	Aβ pathology (Figure 4e). There 





4  |  SUMMARY AND CONCLUSIONS
Q134R is a novel small chemical compound with cytoprotective 
and cognitive enhancing properties. The present work suggests 





ify the actions of Q134R on multiple neural cell types and multi-
ple	NFAT	isoforms.	Nonetheless,	the	overall	safety	and	efficacy	of	
Q134R would seem to make this drug a prime candidate for further 
investigation	in	human	clinical	trials	as	a	primary	therapeutic,	or	at	
the	 least,	 as	a	compliment	 to	other	 therapeutics,	 including	other	
CN inhibitors.
5  |  MATERIAL S AND METHODS
5.1  |  Q134R
Q134R	was	synthesized	by	Avidin	Ltd.	as	described	previously	and	
used	 in	 cell	 culture	 conditions	 at	 similar	 concentrations	 (Hackler	
et	 al.,	 2019).	 The	 pharmacokinetic	 properties	 of	Q134R	were	 de-
termined earlier during preclinical development using radioactive- 
labeled	Q134R	(CLINICAL	INVESTIGATOR'S	BROCHURE,	Q134R-	K,	
January	12,	2016).	In	male	rats,	organ/tissue	concentrations	of	total	
radioactivity [μgE/g were measured (Dose: 10 mg/kg [14C]- Q134R 
    |  13 of 20SOMPOL et aL.
orally as potassium salt). The absorbed radioactivity showed rela-
tively	weak	 distribution	 properties.	 At	 1-	hr	 post-	dose,	 tissue	 con-
centrations	of	Q134R	(0.879	μgE/g) were markedly higher than the 
blood concentration. The brain levels of Q134R were similar to the 
blood	level	(0.963	μgE/g). The determined peak concentration in the 
brain was comparable to effective concentrations determined in 
vitro	for	NFAT	inhibitory	activity.
5.2  |  Primary astrocyte cultures and 
drug treatments
Primary cortical astrocytes were prepared from embryonic mouse 
pups and grown to confluence as previously described (Furman 
et	al.,	2010;	Sama	et	al.,	2008).	Once	cells	were	confluent,	cultures	
were washed twice with Ca2+	 and	Mg2+- free phosphate- buffered 






that	is,	phorbol	ester/ionomycin,	IL-	1β,	or	oAβ peptides. Ionomycin 
and	phorbol	ester	 (EMD	Millipore)	were	each	prepared	as	a	2	mM	
stock and used at a concentration of 1 μM.	IL-	1β (Pepro Tech) was 
prepared as a 20 μg/ml	stock	solution	in	0.1%	bovine	serum	albumin	
(BAS)	 and	used	at	 a	 final	 concentration	of	10	ng/ml.	 Synthetic	Aβ 
peptides	(rPeptide)	were	dissolved	in	DMSO	(100	μg/ml) and added 
to	 sodium	phosphate	buffer	 (50	mM	NaPi,	150	mM	NaCl,	pH	7.5)	
at a final concentration of 2 μg/ml and incubated at room tempera-




1 ml fractions were collected and peptide concentrations deter-
mined	by	 sandwich	ELISA	 as	 described	previously	 (LeVine,	 2004).	
CN	autoinhibitory	peptide	(AIP,	from	EMD	Millipore)	was	prepared	
as a 500 μM	stock	in	serum-	free	cell	culture	medium	and	used	at	a	




5.3  |  NFAT luciferase assays
Primary	 astrocytes	 were	 prepared	 as	 described	 above,	 except	
an	NFAT	 luciferase	 adenovirus	 (Ad-	Luc)	was	 added	 to	 the	 serum-	
free	medium	so	 that	 the	cells	were	 infected	with	50	MOI	of	virus	
per	 our	 previous	 studies	 (Furman	 et	 al.,	 2010;	 Sama	 et	 al.,	 2008).	
Inhibitors	and	activators	were	added	as	above,	using	the	indicated	
concentrations of Q134R for dose- inhibition curves. Cells were 
maintained	 in	NFAT	 stimulatory	 agents	 for	 4–	5	 hrs	 in	 serum-	free	
medium,	 then	harvested	 for	 luciferase	 assays	by	washing	 cultures	
twice with Ca2+/Mg2+-	free	phosphate-	buffered	saline,	then	adding	
M-	PER	Mammalian	Protein	Extraction	Reagent	 (Thermo	Scientific,	





5.4  |  Western blot
Cultures were placed on an ice pack and washed twice with PBS with 
cell-	permeable	phosphatase	 inhibitors	 (Activ	Motif,	Carlsbad,	CA).	
After	washing,	0.4	ml	of	phosphatase-	inhibitor	buffer	was	added	to	





Cat	 No.	 524625),	 phosphatase	 inhibitor	 cocktail	 (Calbiochem	 Cat	
No	 539134),	 and	 calpain	 inhibitor	 cocktail	 (Calbiochem	 Cat	 No.	
208733).	After	resuspending	each	pellet,	60	µl	of	4X	sample	buffer	
and	24	µl	of	1	M	DTT	were	added	and	the	samples	were	heated	at	




Lincoln,	NE),	 and	 put	 into	 primary	 antibodies	 in	 equal	 volumes	 of	
blocking buffer and PBS- Tween overnight: 1:2000 rabbit Na+/K+ 
ATPase	 (Abcam,	 loading	 control,	 Cat.	 No.	 ab76020),	 1:1000	 rab-
bit	 anti-	 Cx43	 (Cell	 Signaling,	 Cat.	No.	 3512S),	 1:500	mouse	 anti-	
dephosphorylated	 Cx43	 (Invitrogen,	 Cat.	 No.	 138300).	 Primary	
antibodies	 were	 detected	 with	 800-	mouse	 and	 680-	rabbit	 sec-
ondary	fluorescent	antibodies	(LI-	COR,	Lincoln,	NE)	on	an	Odyssey	






5.5  |  In Vitro calcineurin phosphatase 
inhibition assay
In	vitro	CN	activity	was	assessed	using	a	kit	from	Abcam	(Cat.	No.	
ab139461)	 according	 to	 the	 manufacturer's	 directions.	 Briefly,	 a	
standard curve of known PO4
3− concentrations was established ac-
cording	 to	 phosphate	 standards	 provided	 in	 the	 kit.	A	 timecourse	
of CN- dependent dephosphorylation of a phosphopeptide sub-
strate (provided by the kit) was first carried out to determine op-
timal	lead	times	for	inhibition	studies.	Once	optimized,	CN	activity	




3− released from the phosphopeptide was estimated 
using a standard curve.









tions	 (a	12-	hr	 light/dark	cycle	with	 lights	on	 from	07:00–	19:00	hr)	
and had free access to chow and water until behavioral testing.
5.6.1  |  APP/PS1	mice	and	Q134R	treatment
Twelve-	month-	old	 male	 APP/PS1	 mice	 and	 their	 wild-	type	
C57BL/6	 J	 littermates	 received	4	mg/kg	Q134R	or	 vehicle	 twice	
daily	(at	8.00	am	and	4.00	pm)	for	7	days	via	oral	gavage.	On	day	
7,	mice	were	tested	on	the	Y	maze.	Q134R	was	dissolved	 in	10%	
nonionic detergent solution. The nonionic detergent solution was 
prepared	 by	 mixing	 3x	 volume	 of	 polyethylene	 glycol	 (average	
molecular	weight	200,	 Sigma	Aldrich,	Germany)	 and	1	volume	of	
Kolliphor®	HS	15	(BASF,	Germany)	with	36x	volume	of	sterile	dis-
tilled water. Each day mice were weighed and the administration of 
Q134R	or	vehicle	was	carried	out	using	22G	oral	gavage	syringes	
(Kent	Scientific,	USA).
5.6.2  |  Intracranial	delivery	of	oligomeric	Aβ 






prepared	oAβ peptides (50 pmol in 1 μL;	0.1	M	phosphate-	buffered	
saline	 (pH	7.4))	 or	 vehicle	 (0.1	M	phosphate-	buffered	 saline)	were	
injected	 into	 the	 right	 ventricle	with	 stereotaxic	 coordinates	 from	
the	bregma	(AP	−0.22,	L	−1.0	and	D	2.5	in	mm).	Injections	were	made	




2×	 daily)	 as	 described	 above	 and	 then	 treated	 for	 four	 additional	
days	until	Y-	maze	testing.
5.6.3  |  Novel	arm	Y-	maze	test	of	APP/PS1	mice
Testing	 occurred	 in	 a	Y-	shaped	maze	with	 three	 transparent	 plas-
tic	arms	(55	×	15	×	20	cm)	at	a	120°	angle	from	each	other.	There	
were	different	signs	(circle,	rectangle,	and	square)	on	the	top	of	each	
arm and different figures beside the walls and at the end of each 
arm.	 Three	 different	 arms	were	 specified	 in	 advance:	 “Start	 arm,”	
“Familiar	arm,”	and	“Baited	arm.”	Two	arms	from	the	three	(Start	and	




of	 two	sessions.	 In	 the	first,	or	habituation,	session	one	arm	 (later	
Baited	arm)	was	blocked	with	a	nontransparent	wall.	One	hour	later,	
in	the	second	or	test	session,	the	Baited	arm	was	opened.	 In	both	
sessions,	 each	mouse	was	allowed	 to	explore	 the	maze	 for	4	min,	
and	between	habituation	and	test	trials	mice	were	allowed	to	relax	
in their home cage. Each mouse started from the end of the Start 
arm. Dwell times were recorded for Familiar and Baited arms to cal-







Seven	days	prior	 to	 the	experiment	all	 animals	were	 familiarized	
with	the	room,	staff,	smells,	and	noises.	Each	mouse	was	treated	
with	 a	 test	 drug	 or	 its	 vehicle	 2	 hours	 prior	 to	 its	 Y-	maze	 run.	
During	the	test,	each	mouse	was	allowed	to	explore	the	maze	for	
4 min and we accepted a run as successful above 10 or more al-
ternations (total alternations). Each mouse was started from the 
center	of	 the	maze.	The	number	of	 arm	entries	 and	 the	number	





experimental	 setups	was	 thoroughly	 cleaned	with	70%	EtOH,	 fol-
lowed	by	dH2O.	By	using	a	ceiling-	mounted	CCD	camera,	all	trials	
were	recorded	with	Ethovision	XT10	Software	(Noldus,	Netherlands).
5.7  |  Chronic Q134R delivery to mice, blood 
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EDTA-	coated	micro	tubes.	Blood	was	collected	immediately	before	
the initiation of vehicle or Q134R treatment (baseline) and then 
again at 1 and 3 months after twice- daily delivery of vehicle or 
Q134R	(4	mg/kg)	via	oral	gavage,	as	described	above.	Cell	counts	for	
white	blood	cells,	 lymphocytes,	monocytes,	neutrophils,	red	blood	






tial	densities	of	 four	per	 cage	with	 free	access	 to	 sterilized	VRF-	1	
food	 (Akronom	 Ltd.	 Budapest,	 Hungary)	 and	 water.	 Mice	 were	
held	 in	 individually	 ventilated	 cages	 (IVC	 System,	 Suzhou	 Fengshi	
Laboratory	Animal	Equipment	Co.	Ltd.	China).	Starting	at	approxi-
mately	12	months	of	age,	Q134R	(4	mg/kg)	or	vehicle	was	delivered	




5.8  |  Chronic Q134R delivery to mice and AD 
biomarker measures
5.8.1  |  Animals	and	Q134R	administration
Six-	month-	old	 APP/PS1	 mice	 and	 their	 wild-	type	 (C57BL/6	 J)	 lit-
termates	were	treated	with	vehicle	or	4	mg/kg	Q134R	2×	daily	for	
3	months	via	oral	gavage	as	described	above.	Mice	were	housed	3–	4	
per cage under standard light/dark (12 hr:12 hr) conditions at the 
University of Kentucky and provided free access to water and food 
pellets.	All	animals	were	treated	in	accordance	with	the	University	
of	Kentucky	Institutional	Animal	Care	and	Use	Committee	and	ac-







Free	 floating	 brain	 sections	 were	 labeled	 to	 visualize	 Aβ,	 Iba-	1,	
GFAP,	 and	 NFAT4.	 Briefly,	 sections	 were	 first	 washed	 three	 times	
(1X	PBS/0.1%	Triton	X)	for	10’,	room	temperature	(RT),	on	a	shaker.	
The	 sections	were	 then	blocked	 for	peroxidase	using	3%	hydrogen	
peroxide	 in	methanol	 for	30’,	RT,	on	a	 shaker.	DAPI	stain	was	 then	
incubated	 with	 the	 sections	 at	 a	 concentration	 of	 1:1000	 for	 10’,	
RT,	 covered	 from	 light.	 All	 subsequent	 steps	 were	 light-	sensitive	
and protected from direct light. The sections were again washed 
3x	10’	RT	on	a	 shaker.	Blocking	buffer	was	applied	 to	 the	 sections	
(1xPBS/0.1%Triton	X	+	0.03	g/ml	bovine	serum	albumin)	for	30’,	RT,	





















traced and then the software was used to calculate the area that 




confocal Tie2 microscope and NIS software (Nikon).
5.9  |  Chronic Q134R delivery to mice and 
electrophysiology




All	 techniques	 for	 preparing	 acute	 brain	 slices	 and	 assessing	 hip-
pocampal synaptic function are nearly identical to our previous pro-
tocols	(Furman	et	al.,	2012;	Mathis	et	al.,	2011;	Sompol	et	al.,	2017).	
Briefly,	after	3	months	of	vehicle/drug	treatment,	mice	were	euth-
anized	via	CO2	 asphyxiation	and	brains	were	 rapidly	 removed	and	
briefly	(1–	2	min)	stored	in	ice-	cold	oxygenated	(95%	O2/5%	CO2	mix),	
Ca2+-	free	 artificial	 cerebral	 spinal	 fluid	 (ACSF)	 prior	 to	 sectioning.	
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ACSF	consisted	of	(in	mM):	124	NaCl,	2	KCl,	1.25	KH2PO4,	2	MgSO4,	
26	NaHCO3,	and	10	dextrose,	pH	7.4.	Coronal	brain	slices	(400	µm)	
were	 prepared	 on	 a	 Vibratome	 (Leica	 Biosystems,	 Richmond,	 IL)	
in	 ice-	cold	 oxygenated	 Ca2+-	free	 ACSF	 and	 then	 transferred	 to	 a	
custom,	 humidified	 interface	 chamber	where	 they	were	 stored	 in	
warmed (32℃)	oxygenated	ACSF	containing	2	mM	CaCl2 until elec-
trophysiologic	analyses	of	hippocampal	CA3-	CA1	synaptic	function.
5.9.2  |  Population	synaptic	strength	measures
Slices were transferred to a Kerr Tissue Recording system (Kerr 
Scientific Instruments) and submerged in warmed (∼32℃)	oxygenated	
aCSF	 containing	2	mM	CaCl2	 and	2	mM	MgSO4. Schaffer collater-
als were activated with a bipolar stainless steel electrode located in 
stratum radiatum. Stimulus intensity was controlled by a constant cur-
rent	stimulus	isolation	unit	(World	Precision	Instruments),	and	stimu-
lus	 timing	was	 controlled	 by	 LabChart	 8	 software	 (ADInstruments;	
RRID:	SCR_001620).	Field	potentials	were	 recorded	 in	CA1	stratum 
radiatum	 using	a	Ag/AgCl	wire	 located	∼1– 2 mm from the stimulat-
ing	electrode.	Field	potentials	were	amplified	100X	and	digitized	at	
10	kHz	using	the	Kerr	Tissue	Recording	System	amplifier	and	a	4/35	
PowerLab	 analog-	to-	digital	 converter	 (ADInstruments).	 To	 assess	
basal	synaptic	strength,	100	μs stimulus pulses were given at 12 inten-
sity	levels	(range,	25–	500	μA)	at	a	rate	of	0.1	Hz.	Five	field	potentials	at	
each	level	were	averaged,	and	measurements	of	fiber	volley	(FV)	am-
plitude (in mV) and EPSP slope (mV/ms) were performed offline using 
the	LabChart	8	software.	Synaptic	strength	curves	were	constructed	
by plotting EPSP slope values against FV amplitudes for each stimu-
lus	level.	To	calculate	paired-	pulse	facilitation	(PPF),	the	average	EPSP	
slope was measured along the linear portion of the synaptic strength 
curve	(at	50-	100uA	stimulation).	Then,	the	EPSP	slope	of	S2	was	di-
vided by the EPSP slope of S1 and multiplied by 100. The EPSP slope at 











Synaptic parameters were averaged across slices within each animal to 
get	a	single	data	point	per	animal.	Thus,	n	for	each	experiment	reflects	
the number of animals included in each treatment group.
5.9.3  |  Statistics
All	 statistical	 analyses	 were	 performed	 using	 GraphPad	 Prism	
v7	 (GraphPad	 Software,	 San	 Diego,	 CA).	 Student's	 t tests were 
used to evaluate differences between the two treatment groups. 
Comparison of two or more genotype/treatment groups was made 
using	one-	way	or	two-	way	analysis	of	variance	(ANOVA),	followed	
by	 Fisher's	 LSD	 post	 hoc	 tests.	 The	 Log-	rank	 test	 and	 Gehan–	
Breslow–	Wilcoxon	 test	 were	 used	 to	 compare	 survival	 curves	
between vehicle and Q134R- treated mice. Significance for all statis-
tical comparisons was set at p	≤	0.05.
6  |  SUPPLEMENTARY METHODS




ing	10%	FBS	 (Gibco)	at	37℃	 in	a	5%	CO2 atmosphere. For the inhi-
bition	experiments,	2	×	104	 cells	were	 seeded	 in	96	well	 plates	 and	
incubated overnight. Cells were treated with an increasing concentra-







Primary cortical neurons were prepared as described previously 
(Sama	 et	 al.,	 2008).	 Briefly,	 cortical	 tissue	 dissected	 from	 E18	
Sprague– Dawley rat pups was passed through a glass pipette and 
filtered through a 0.22- micron nylon mesh. Following centrifuga-








erase assays as described above for astrocytes. Statistical analyses 
were performed as described in Figure 1.
6.2  |  Immunofluorescence labeling for 
NFAT3 and MAP2B
APP/PS1	mice	 and	WT	 littermates	 treated	 chronically	with	 ve-
hicle	 (WT	 vehicle,	 n	 =	 12;	 APP/PS1	 vehicle,	 n	 =	 17)	 or	Q134R	
(4	mg/kg,	2×/day	P.O.	 for	3	months)	 (WT	Q134R,	n	=	14;	APP/
PS1	Q134R,	n	=	20).	Mice	were	6-	months	of	age	when	treatment	
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began. Brains were harvested and prepared for immunofluo-
rescent labeling as described in Figures 4 and 5. Images were 
taken using a Nikon confocal Tie2 microscope and NIS soft-
ware	 (Nikon).	 For	 each	 animal,	 an	 image	 of	 the	 CA1	 region	 of	
the	 hippocampus	 was	 taken	 at	 60x	 magnification,	 using	 the	
large	 image	 setting	 to	 take	2x2	 image	 fields	with	a	5%	overlap	
stitching.	Furthermore,	each	 image	consisted	of	z-	stacks	to	en-
compass a 16 μm thickness for each section at 1 μm intervals 
(17	 z	 levels	 total).	 After	 capturing	 the	 images,	 the	 amount	 of	





mask the positive signal of each fluorophore within the region of 
interest	and	applied	 to	each	z-	level	of	 the	captured	 images.	By	
combining	the	binary	(fluorophore	positive)	areas	across	each	z	
level,	we	obtained	a	volume	of	positive	 fluorophore	 signals	 for	
each region of interest. The three ROIs for each cellular region 
were then averaged together and reported. Statistical analyses 
were performed as described in Figures 4- 5.
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